MedTrace Logo

The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis

NCT01769898 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-11

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy and safety of 24 weeks treatment with theophylline plus low-dose formoterol-budesonide in subjects with bronchiectasis.

Conditions

Interventions

DRUG

Formoterol-budesonide

Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)

DRUG

Theophylline

Theophylline 0.1 Q12H

DRUG

Placebo

Placebo for theophylline 0.1 Q12H

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Chen Rongchang, Professor · institute vice director

  • Zhong Nanshan, Professor · institute director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-09-30
Completion
2014-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01769898 on ClinicalTrials.gov